The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 55 - Any |
| Updated: | 2/6/2019 |
| Start Date: | January 2017 |
| End Date: | March 2019 |
Antipsychotic Use Within the Program of All-inclusive Care for the Elderly (PACE)
The aim of this study is to retrospectively evaluate and describe the use of antipsychotics
among participants enrolled in the Program of All-inclusive Care for the Elderly (PACE), a
community-based practice setting.
among participants enrolled in the Program of All-inclusive Care for the Elderly (PACE), a
community-based practice setting.
Much national attention has been given to assessing and reducing the use of antipsychotics
among nursing home residents, yet comparatively little attention has focused on antipsychotic
use among older adults receiving care in community-based settings. The primary objective of
this study is to determine the prevalence of antipsychotic use among a nationally
representative sample of nursing home-eligible older adults in a community-based practice
setting known as Program of All-inclusive Care for the Elderly (PACE). The secondary
objectives are focused on characterizing antipsychotic use within PACE and for these
participants. Specifically, the investigator's secondary objectives are to describe patterns
of other drugs concomitantly used with antipsychotics (e.g., benzodiazepines, opioids) and to
identify clinically relevant drug-drug interactions involving antipsychotics.
among nursing home residents, yet comparatively little attention has focused on antipsychotic
use among older adults receiving care in community-based settings. The primary objective of
this study is to determine the prevalence of antipsychotic use among a nationally
representative sample of nursing home-eligible older adults in a community-based practice
setting known as Program of All-inclusive Care for the Elderly (PACE). The secondary
objectives are focused on characterizing antipsychotic use within PACE and for these
participants. Specifically, the investigator's secondary objectives are to describe patterns
of other drugs concomitantly used with antipsychotics (e.g., benzodiazepines, opioids) and to
identify clinically relevant drug-drug interactions involving antipsychotics.
Inclusion Criteria:
- Participant enrolled in PACE contractually receiving pharmacy services from Tabula
Rasa Healthcare CareKinesis Pharmacy (Tabula Rasa HealthCare) during the project time
period (January 2017 through December 2017).
Exclusion Criteria:
- Participant with a diagnosis of bipolar disorder and/or schizophrenia, according to
pharmacy records.
We found this trial at
1
site
Click here to add this to my saved trials
